Journal Watch · Journal of Controlled Release · 2026
β-glucuronidase-triggered ortho-hydroxyl-mediated cyclization strategy for the efficient delivery of phenolic payloads in antibody-drug conjugates.
This study establishes a robust platform for overcoming the synthetic and kinetic hurdles associated with phenolic ADCs.
TL;DR
This study establishes a robust platform for overcoming the synthetic and kinetic hurdles associated with phenolic ADCs.
Key findings
- Notably, at equivalent doses, the lead candidate Tras-GLU579 achieved profound tumor regression with a T/C value of 2.33% on day 20, significantly outperforming the benchmark (T/C = 18.58%; p < 0.01), while maintaining a favorable safety profile.
- This study establishes a robust platform for overcoming the synthetic and kinetic hurdles associated with phenolic ADCs.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Triggered by β-glucuronidase, an enzyme overexpressed in the tumor microenvironment, this system utilizes a hydrophilic glucuronide moiety that not only ensures tumor-specific activation but also improves the hydrophilicity of ADCs compared to traditional hydrophobic linkers. We synthesized trastuzumab-based conjugates utilizing this novel strategy (Tras-GLU572 and Tras-GLU579) and compared them against a clinical benchmark ADC utilizing a conventional peptide linker (Tras-GGFG-DXd). In HER2-positive NCI-N87 xenograft models, the optimized conjugates, Tras-GLU572 and Tras-GLU579, exhibited superior antitumor efficacy compared to the benchmark Tras-GGFG-DXd.
Full abstract (original)
Background: While the payload landscape of antibody-drug conjugates (ADCs) has diversified beyond amine-containing compounds, the application of potent cytotoxic agents possessing phenolic hydroxyl groups remains restricted. This is primarily due to the scarcity of linker technologies capable of balancing systemic stability with efficient release kinetics, as conventional strategies for phenolic conjugation often suffer from premature hydrolysis or sluggish activation. Herein, we report the design and evaluation of a novel self-immolative linker strategy based on an ortho-hydroxyaniline scaffold, which facilitates the efficient release of phenolic payloads via intramolecular cyclization.
What they did: Triggered by β-glucuronidase, an enzyme overexpressed in the tumor microenvironment, this system utilizes a hydrophilic glucuronide moiety that not only ensures tumor-specific activation but also improves the hydrophilicity of ADCs compared to traditional hydrophobic linkers. We synthesized trastuzumab-based conjugates utilizing this novel strategy (Tras-GLU572 and Tras-GLU579) and compared them against a clinical benchmark ADC utilizing a conventional peptide linker (Tras-GGFG-DXd). In HER2-positive NCI-N87 xenograft models, the optimized conjugates, Tras-GLU572 and Tras-GLU579, exhibited superior antitumor efficacy compared to the benchmark Tras-GGFG-DXd.
Results & conclusions: Notably, at equivalent doses, the lead candidate Tras-GLU579 achieved profound tumor regression with a T/C value of 2.33% on day 20, significantly outperforming the benchmark (T/C = 18.58%; p < 0.01), while maintaining a favorable safety profile. This study establishes a robust platform for overcoming the synthetic and kinetic hurdles associated with phenolic ADCs.
Abstract © the authors / Journal of Controlled Release (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jconrel.2026.114873 · PubMed 41903751.
Why it matters for pharma & biotech
- Directly relevant to teams in antibody / ADC therapeutics, targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: antibody / ADC therapeutics · targeted oncology / immuno-oncology
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
Frequently asked questions
What did this Journal of Controlled Release study find?
This study establishes a robust platform for overcoming the synthetic and kinetic hurdles associated with phenolic ADCs.
What type of study is this?
It is a preclinical (animal / model) study, published in Journal of Controlled Release in 2026. Triggered by β-glucuronidase, an enzyme overexpressed in the tumor microenvironment, this system utilizes a hydrophilic glucuronide moiety that not only ensures tumor-specific activation but also improves the hydrophilicity of ADCs compared to traditional hydrophobic linkers.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.jconrel.2026.114873. PubMed ID: 41903751. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/glucuronidase-triggered-ortho-hydroxyl-mediated-cyclization-strategy-for-114873/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides